BDRX News and Press, Biodexa Pharmaceuticals PLC-ADR From 05/22/24

2024-05-22 08:55:00 ET More on Biodexa Pharmaceuticals Biodexa rallies 80% on positive Phase 2 data for eRapa Biodexa shares rally 126% on rapamycin licensing deal Read the full article on Seeking Alpha For further details see: Biodexa Pharmaceuticals rec...

May 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Fundin...

2024-05-22 06:52:00 ET 3 Top Tips to Find Penny Stocks Before They Explode in Price Investing in penny stocks can offer significant returns, making it an attractive option for investors looking to expand their portfolios with potentially high-growth assets. While the allure of turning s...

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 62.7% to $0.0589 on volume of 663,531,193 shares MGO Global Inc. (MGOL) rose 443.7% to $1.25 on volume of 324,879,411 shares Crown Electrokinetics Corp. (CRKN) fell 36.8% to $0.1257 on v...

2024-05-21 11:37:31 ET Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) opened more than 100% up on Tuesday after reporting encouraging Phase 2 data for eRapa. Details of the Phase 2 data reported today The recently licensed drug for FAP (familial adenomatous polyposis) showed non-pro...

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 55.1% to $0.071 on volume of 238,137,489 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 29.4% to $0.1679 on volume of 103,146,154 shares MGO Global Inc. (MGOL) rose 206.7% to $0.7051 ...

2024-05-21 09:40:26 ET More on Biodexa Pharmaceuticals Biodexa shares rally 126% on rapamycin licensing deal Biodexa stock slides 7% amid data for two drug studies Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Bio...

May 21, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation a...

May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pi...

Registrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by Biodexa, its second portfolio expansion in less than six months, and is supported by a $17 million g...